While Congress continues to consider significant reforms for drug pricing, states have taken bold steps to control drug prices across payers. This legislative session, Colorado followed Maryland’s lead and established a prescription drug affordability board (PDAB) to address high drug prices. PDAB legislation, such as Maryland’s and Colorado’s, that includes authority for a board to […]
Author Archive for: jennifer-reck
About Jennifer Reck
Jennifer Reck is project director of NASHP’s Center for State Prescription Drug Pricing. The center works with states to develop model policies to address drug prices, tracks legislation and implementation, and provides technical assistance. Since joining NASHP in 2015, she has designed and implemented technical assistance for state learning collaboratives to advance evidence-based policymaking and alternative payment models. She has also directed evaluation teams analyzing delivery system and payment reforms, including State Innovation Models, and led efforts to disseminate findings from a federal initiative to advance evidence-based preventive care.
Prior to joining NASHP in 2015, Jennifer was Maine Medical Association’s (MMA) director of grants management, where she engaged physicians in payment reform as well as outreach and advocacy efforts to implement the Affordable Care Act. She also directed the MMA’s academic detailing program – the Maine Independent Clinical Information Service – an educational outreach program to promote evidence-based primary care. She has also worked as a policy analyst at Prescription Policy Choices, providing states with policy models and technical assistance to address clinical and cost concerns related to prescription drugs, and as a publishing editor at Elsevier Science, managing its portfolio of health policy journals.
She received her master’s degree from Cornell University in Science and Technology Studies and her bachelor’s degree in the history and philosophy of science from Bard College.
Entries by Jennifer Reck
States and other stakeholders have another chance to weigh in on Tennessee’s 10-year Medicaid funding demonstration which was approved by the Centers for Medicare & Medicaid Services (CMS) in early January during the final days of the Trump administration. In April, two legal advocacy organizations sued the federal government to block the demonstration, though the plaintiffs have since agreed to pause the lawsuit on the condition that a new federal […]
The recent approval of the Alzheimer’s drug Aduhelm under the U.S. Food & Drug Administration’s (FDA) Accelerated Approval Program is controversial for a range of reasons, including its projected impact on state Medicaid budgets which will be required to cover the drug, priced at $56,000 a year, despite inconclusive evidence of its clinical effectiveness. While Aduhelm is the latest prescription drug to make headlines, state Medicaid programs have been seeking policy solutions to address high cost accelerated […]
On May 28, 2021, the U.S. Department of Health and Human Services (HHS) filed a motion urging a District Court to dismiss the Pharmaceutical Research & Manufacturers of America’s (PhRMA) challenge to a federal rule enabling state importation from Canada. The filing signaled the Biden administration’s commitment to defend the rule, which was published in October 2020 under the previous administration. HHS argued that PhRMA lacked standing to pursue the suit because manufacturers have not been harmed by […]
Democrats in the US House of Representatives recently reintroduced their comprehensive prescription drug pricing reform bill, HR 3, and held hearings on drug pricing. However, prospects for enacting this legislation remains uncertain. In the meantime, states are moving forward with their own efforts to lower drug costs, many of which align with provisions in HR 3. First passed by the House in December 2019, HR 3 includes provisions that would, among other things: Allow the US Department of […]
More than 200 bills to lower drug prices have been filed across states during this session and nine states are proposing prescription drug affordability board (PDAB) legislation.
Three states have proposed legislation, based on National Academy for State Health Policy’s model law, that penalizes drug manufacturers for hiking prescription drug prices without new clinical evidence to justify the increase.
As states take important steps to lower prescription drug costs, at least six have implemented prescription drug affordability review initiatives, although approaches vary across states. The National Academy for State Health Policy (NASHP)’s new chart, Comparison of State Prescription Drug Affordability Review Initiatives, provides a road map of the diverse efforts taken by Maryland, Maine, […]
Burdened by high US drug prices that average 218 percent more than in Canada, innovative states across the country are exploring a range of approaches to give their residents the same access to affordable drugs Canadians have. To date, six leading states have passed laws that enable them to import drugs from Canada pending federal […]
In late December, a US District Court judge in the Eastern District of California upheld that state’s drug price transparency law. The ruling represents the latest legal victory for states working to curb drug prices following the December Supreme Court decision that upheld an Arkansas law regulating pharmacy benefit managers (PBMs). California’s drug price transparency law, SB17, requires […]